New Evidence in Heart Failure: 2026 Update
ESC Heart Failure · 01.09.2026
DOI: 10.1093/eschf/xvag216 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 01.09.2026. Verfasst von Valentino Liguori und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, ASST Spedali Civili, University of …. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) remains a major cause of morbidity, mortality, impaired quality of life and healthcare expenditure worldwide. The global burden of HF continues to increase due to population aging, improved survival, and the growing prevalence of cardiovascular, renal, and metabolic comorbidities. Simultaneously, the pace of scientific progress in HF has accelerated considerably. Recent advances have refined our understanding of HF epidemiology, prognosis, and disease trajectories, including emerging concepts of HF improvement, remission, and recovery. The Second Universal Definition of HF has also updated the classification framework, moving beyond the traditional ejection fraction-based categories. HF is now broadly classified into two major phenotypes: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Novel mechanistic insights highlight the role of inflammation, immune activation, metabolic dysfunction, mitochondrial biology, and multisystem interactions in HF progression. There has also been significant progress in the characterization and management of major comorbidities, including chronic kidney disease (CKD), diabetes, obesity, atrial fibrillation (AF), pulmonary hypertension, frailty, malnutrition, and cancer. Diagnostic innovations include novel biomarkers, multi-omics technologies, artificial intelligence-based approaches, advanced imaging techniques, congestion assessment tools, and emerging digital health solutions. Important advances have occurred in specific HF aetiologies, including cardiomyopathies, cardiac amyloidosis (CA), myocarditis, arrhythmia-induced cardiomyopathy (AiCM), and Chagas cardiomyopathy. Therapeutic developments continue to reshape HF management across the spectrum of left ventricular ejection fraction. Recent evidence has focused on optimization of guideline-directed medical therapy in HFrEF, expansion of evidence-based therapies in HFpEF, and growing roles for sodium–glucose cotransporter-2 inhibitors, finerenone, incretin-based therapies, and transcatheter valve interventions. Collectively, these advances support the transition from a predominantly phenotype-based approach towards a more personalized and biologically informed model of HF care, with the potential to further improve outcomes across the entire HF spectrum.
Autor:innen und Institutionen
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, ASST Spedali Civili, University of Brescia, Brescia, Italy.
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
- Departments of Internal Medicine and Cardiology, Angiology and Intensive Care Medicine, Saarland University, Saarbrücken, Germany.
- Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wrocław, Poland.
- Department of Cardiology, Wroclaw Medical University Hospital, Wrocław, Poland.
ORCID-Profile: Valentino Liguori, Marianna Adamo, Zoltán Papp, Gianluigi Savarese, Jan Biegus, Daniela Tomasoni
Zitieren
APA
Liguori, V., Rizzello, A., Adamo, M., Aimo, A., Böhm, M., Papp, Z., Ponikowski, P., von Haehling, S., Zymliński, R., Savarese, G., Metra, M., Biegus, J., & Tomasoni, D. (2026). New Evidence in Heart Failure: 2026 Update. ESC Heart Failure. https://doi.org/10.1093/eschf/xvag216
Vancouver
Liguori V, Rizzello A, Adamo M, Aimo A, Böhm M, Papp Z, et al. New Evidence in Heart Failure: 2026 Update. ESC Heart Failure. 2026. doi:10.1093/eschf/xvag216
BibTeX
@article{Liguori2026,
author = {Liguori, Valentino and Rizzello, Angelica and Adamo, Marianna and Aimo, Alberto and Böhm, Michael and Papp, Zoltán and Ponikowski, Piotr and von Haehling, Stephan and Zymliński, Robert and Savarese, Gianluigi and Metra, Marco and Biegus, Jan and Tomasoni, Daniela},
title = {New Evidence in Heart Failure: 2026 Update},
journal = {ESC Heart Failure},
year = {2026},
doi = {10.1093/eschf/xvag216}
}
EUVIMED